Hengrui Pharma Reports 2025 Revenue of RMB 31.63 Billion

Hengrui Pharma (600276.SH; 01276.HK) reported robust financial results for the full year 2025 on March 25, 2026. The company's revenue rose 13.02% year-on-year to RMB 31.63 billion (approximately USD 4.3 billion), while net profit attributable to shareholders increased by 21.69% to RMB 7.71 billion (approximately USD 1.06 billion).

The company's growth was significantly driven by its innovative drugs, which saw a 26.09% increase in sales, reaching RMB 16.34 billion. These innovative products accounted for 58.34% of total drug sales, with oncology products generating RMB 13.24 billion and non-oncology products contributing RMB 3.10 billion.

Hengrui Pharma maintained a strong focus on research and development, with R&D expenditure totaling RMB 8.72 billion, representing 27.58% of total revenue. During the year, the company received approvals for seven new innovative drugs and one new Class 2 innovative drug. Furthermore, 15 new drug applications (NDA/BLA) were accepted for review by China’s NMPA.

The company also reported progress in its global expansion efforts. Licensing revenue increased by 25.62% to RMB 3.39 billion. Hengrui Pharma completed five overseas business development transactions, including a notable collaboration with GSK. The company also successfully listed on the Hong Kong Stock Exchange, raising USD 1.5 billion in what was the largest pharmaceutical IPO in Hong Kong in five years.

Hengrui Pharma stated it will continue to focus on addressing unmet clinical needs through its innovative portfolio and collaborations, aiming to expand patient access to new medicines worldwide.